|Articles|May 19, 2015

Special Reports

  • Genitourinary (Issue 2)
  • Issue 2

AR-V7 as a Biomarker in CRPC

Emmanuel S. Antonarakis, MBBCh, Johns Hopkins Medicine, discusses the potential of AR-V7 as a biomarker in early stage castration-resistant prostate cancer (CRPC).

Emmanuel S. Antonarakis, MBBCh, Johns Hopkins Medicine, discusses the potential of AR-V7 as a biomarker in early stage castration-resistant prostate cancer (CRPC).

<<<

View more from the GU Cancers Special Report


Latest CME